Aldurazyme^®

Aldurazyme^®: MPS I long-term enzyme replacement therapy

Access essential insights for MPS I specialists

Register or log in to access valuable resources about Aldurazyme^®, a therapy designed to treat the non-neurological manifestations of MPS I. You'll receive the latest updates, educational materials^1,10,14,15, and tools to enhance patient care. Sign up now to stay informed and make a difference in your practice.

Aldurazyme Smpc Oct 2019.
Early initiation of Aldurazyme^® has been shown to influence the natural history of MPS I.
O’Connor P, Wolinsky JS, Confavreux C, et al; for the TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
Confavreux C, O’Connor P, Comi G, et al; for the TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-256.
O’Connor P, Comi G, Freedman MS, et al; for the Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920-930.
Case reports of siblings initiating Aldurazyme at different ages highlight the benefits of early treatment in preventing and slowing disease progression.
Aldurazyme has more than 17 years of established safety and tolerability.
Clinical guidelines recommend maintaining regular infusions to manage MPS I symptoms effectively.
Long-term commitment to Aldurazyme treatment is crucial for optimal patient outcomes.
Regular assessments are key to monitoring patient response to Aldurazyme and ensuring optimal management of MPS I.

To continue reading confirm that you are a healthcare professional

Click login to continue

Enter your credentials to access your account

Email address *

Email address is not formatted correctly.

This is a required field

Password *

This is a required field

Remember me

Forgot Password

Don't have an account yet? REGISTER

The account is under our identity verification process. When complete you will receive a confirmation email and you will be able to access the area dedicated to you.

Resend email successful, please check your inbox to verify your account.

To activate your account, you need to verify your email. Please click on the button below to resend a veritifcation link to the email you registered with.

You have a valid login but are missing the roles required to view this page. Please contact support.

Campus Sanofi KSA

Create Profile

Email sent!

Gain access to scientific resources, events, patient management solutions and product updates.

* Required

Email *

This email is available

This email is already registered. If you have forgotten your password, you can click the "LOGIN" below and click Forgot Password.

You already have an account awaiting email validation. To activate your account now, you can resend verification link to your email by simply trying to LOGIN and clicking on the button “Resend Verification Email”

This email is already registered but pending verification.

There was an error, please contact the administrator of the page.

Password *

1 Capital letter

1 Lowercase letter

1 Number

8 Characters

Confirm Password *

Your passwords match.

First Name *

Last Name *

Workplace Name *

Workplace Sector *

Workplace Type *

City *

Specialty *

Saudi Commission for Health Specialties License *

National ID/Iqama ID *

Areas of interest

By selecting "Areas of interest" you'll help us to improve your experience on Campus Sanofi, allowing to offer you content, tailored to your interests

Allergic Rhinitis *

Asthma *

Atherothrombosis *

Atopic Dermatitis *

Cardiovascular *

Diabetes *

Dyslipidemia *

Eosinophilic Esophagitis (EoE) *

Influenza *

Nasal Polyps *

Neurological Disorders *

Oncology *

Prurigo Nodularis (PN) *

Rare Blood Disorders *

Rare Diseases *

My Consent

I accept treatment of my Personal Information by Sanofi as specified in the Privacy Policy, for the purpose of receiving communications about products, services and customized content through:

SMS

I have been informed that I have the right to object to the processing of my Personal Information for these purposes by refusing to sign this consent or to withdraw my consent at any time and free-of-charge. In such cases, I understand that no consequences due to such objection will arise except that Sanofi will not be able to provide me with information about its products, services and activities nor be able to provide me with customized pharmaceutical information, based on my preferences and interests.

I have been informed that if I do not longer wish to receive information or communications about particular products and services or from Sanofi (for example, postal mailings, emails and telephone calls), I may opt out of any particular product or service or from all mailings by contacting Sanofi at the following contact information:

engage.gulf@sanofi.com

I understand that an “unsubscribe” option is also available through Sanofi website and that I may also click on the “unsubscribe” link at the bottom of any email from Sanofi and follow the directions that appear on the screen in order to opt out of communications from Sanofi, I understand that I may continue to receive materials for a period of time while Sanofi lists are being updated.

Mobile Phone Number *

I acknowledge having read, understood, and accepted the Legal Notice and Terms and Conditions and Sanofi Privacy Policy.

csspecialtiesSpecialtyType consentDataPrivacy displayName addressCountry cslegalAcceptancesIdentifier Country_3ISO_CODE Country_IDENTIFIER Country_NAME

Already have an account? | LOGIN

Campus Sanofi KSA

Check your email inbox to activate your account

Email sent!

A verification email has been sent to the email you have registered with. To activate your account, please click on the link in this email. If you have not received the verification email, please click on the button below.

Aldurazyme^®

Aldurazyme^®: MPS I long-term enzyme replacement therapy

Access essential insights for MPS I specialists

To continue reading confirm that you are a healthcare professional

Sanofi Preference Center Login

HCP Verification Required

Email Sent!

Email Verification Required

Unauthorized login

Create Profile

Check your email inbox to activate your account

Welcome to Sanofi Campus

You Will Now Be Leaving the Site

Page menu

Aldurazyme®

Aldurazyme®: MPS I long-term enzyme replacement therapy

Access essential insights for MPS I specialists

References

To continue reading confirm that you are a healthcare professional

Aldurazyme^®

Aldurazyme^®: MPS I long-term enzyme replacement therapy